Accellena Research and Development LLC has identified substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl) ethanamines acting as trace amine-associated receptor 1 (TAAR1; TAR1) agonists reported to be useful for the treatment of cardiovascular disorders, diabetes, metabolic diseases, migraine, neurological disorders, obesity, psychiatric disorders and substance abuse and dependence.
Link to original publication
https://www.bioworld.com/articles/695355-accellena-research-and-development-describes-new-taar1-agonists?v=preview
Full article is available for subscribers.
Link to original publication
https://www.bioworld.com/articles/695355-accellena-research-and-development-describes-new-taar1-agonists?v=preview
Full article is available for subscribers.
